Doug Giordano

Doug Giordano is currently a Managing Director at Perceptive Advisers. Prior to joining Perceptive, Doug served as the Senior Vice President, Pfizer Worldwide Business Development Group, from 2007 through 1st Quarter 2021. Doug was responsible for leading Pfizer’s evaluation, negotiation and execution of product licensing, partnerships and M&A transactions. Under Doug’s leadership Pfizer deployed over $125B of capital to business development across a wide range of transaction types from venture investing, biotech licensing through large scale M&A. Doug also led Pfizer’s IPO/split-off of Zoetis, Pfizer’s consumer JV with GSK, Pfizer’s carve out and stand up of companies like Cerevel, Spring Works and Allogene; and the recently closed spin/merger of Viatris.

Before leading Pfizer’s Worldwide Business Development group, Doug held positions of increasing responsibility within Pfizer’s U.S. Pharmaceuticals Group including roles in finance, manufacturing and commercial strategy. Prior to joining Pfizer, Doug was a consultant at Booz, Allen & Hamilton.

Doug earned a bachelor’s degree in Biomedical Engineering from Duke University and an M.B.A. from Cornell University’s Johnson School of Business. He currently serves on the Board of Cerevel Therapeutics and is a member of the Duke University School of Medicine Board of Visitors.